These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 29461635)

  • 21. Investigation of PAX3/7-FKHR fusion genes and IGF2 gene expression in rhabdomyosarcoma tumors.
    de Souza RR; Oliveira ID; Caran EM; Alves MT; Abib S; Toledo SR
    Growth Horm IGF Res; 2012 Dec; 22(6):245-9. PubMed ID: 23079386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting PAK4 Inhibits Ras-Mediated Signaling and Multiple Oncogenic Pathways in High-Risk Rhabdomyosarcoma.
    Dasgupta A; Sierra L; Tsang SV; Kurenbekova L; Patel T; Rajapakse K; Shuck RL; Rainusso N; Landesman Y; Unger T; Coarfa C; Yustein JT
    Cancer Res; 2021 Jan; 81(1):199-212. PubMed ID: 33168646
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrative clinical and biopathology analyses to understand the clinical heterogeneity of infantile rhabdomyosarcoma: A report from the French MMT committee.
    Butel T; Karanian M; Pierron G; Orbach D; Ranchere D; Cozic N; Galmiche L; Coulomb A; Corradini N; Lacour B; Proust S; Guerin F; Boutroux H; Rome A; Mansuy L; Vérité C; Defachelles AS; Tirode F; Minard-Colin V
    Cancer Med; 2020 Apr; 9(8):2698-2709. PubMed ID: 32087612
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A clinicopathologic study of head and neck rhabdomyosarcomas showing FOXO1 fusion-positive alveolar and MYOD1-mutant sclerosing are associated with unfavorable outcome.
    Owosho AA; Huang SC; Chen S; Kashikar S; Estilo CL; Wolden SL; Wexler LH; Huryn JM; Antonescu CR
    Oral Oncol; 2016 Oct; 61():89-97. PubMed ID: 27688110
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group.
    Hibbitts E; Chi YY; Hawkins DS; Barr FG; Bradley JA; Dasgupta R; Meyer WH; Rodeberg DA; Rudzinski ER; Spunt SL; Skapek SX; Wolden SL; Arndt CAS
    Cancer Med; 2019 Oct; 8(14):6437-6448. PubMed ID: 31456361
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A study of alveolar rhabdomyosarcoma copy number alterations by single nucleotide polymorphism analysis.
    Lynn M; Shah N; Conroy J; Ennis S; Morris T; Betts D; O'Sullivan M
    Appl Immunohistochem Mol Morphol; 2014 Mar; 22(3):213-21. PubMed ID: 24614150
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
    Guenther MK; Graab U; Fulda S
    Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of fusion gene status versus histology on risk-stratification for rhabdomyosarcoma: Retrospective analyses of patients on UK trials.
    Selfe J; Olmos D; Al-Saadi R; Thway K; Chisholm J; Kelsey A; Shipley J
    Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28035744
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fusion status in patients with lymph node-positive (N1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: Experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG).
    Gallego S; Zanetti I; Orbach D; Ranchère D; Shipley J; Zin A; Bergeron C; de Salvo GL; Chisholm J; Ferrari A; Jenney M; Mandeville HC; Rogers T; Merks JHM; Mudry P; Glosli H; Milano GM; Ferman S; Bisogno G;
    Cancer; 2018 Aug; 124(15):3201-3209. PubMed ID: 29797665
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The PAX3-FOXO1 fusion protein present in rhabdomyosarcoma interferes with normal FOXO activity and the TGF-β pathway.
    Schmitt-Ney M; Camussi G
    PLoS One; 2015; 10(3):e0121474. PubMed ID: 25806826
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mammalian target of rapamycin pathway activation is associated to RET mutation status in medullary thyroid carcinoma.
    Rapa I; Saggiorato E; Giachino D; Palestini N; Orlandi F; Papotti M; Volante M
    J Clin Endocrinol Metab; 2011 Jul; 96(7):2146-53. PubMed ID: 21543427
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Expression of fusion gene PAX3/PAX7-FKHR and chromosomal aberration in rhabdomyosarcoma].
    Gao H; Ou YL; Zhang KR; Zhang ZB; Wang WL
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Feb; 24(1):42-7. PubMed ID: 17285543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Investigation of IGF2, Hedgehog and fusion gene expression profiles in pediatric sarcomas.
    de Souza RR; Oliveira ID; del Giúdice Paniago M; Yaoita FH; Caran EM; Macedo CR; Petrilli AS; Abib Sde C; de Seixas Alves MT; de Toledo SR
    Growth Horm IGF Res; 2014 Aug; 24(4):130-6. PubMed ID: 24846856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Focusing on organ preservation and function: paradigm shifts in the treatment of pediatric genitourinary rhabdomyosarcoma.
    Shapiro DD; Harel M; Ferrer F; McKenna PH
    Int Urol Nephrol; 2016 Jul; 48(7):1009-13. PubMed ID: 27068815
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival.
    Petricoin EF; Espina V; Araujo RP; Midura B; Yeung C; Wan X; Eichler GS; Johann DJ; Qualman S; Tsokos M; Krishnan K; Helman LJ; Liotta LA
    Cancer Res; 2007 Apr; 67(7):3431-40. PubMed ID: 17409454
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary cilia control hedgehog signaling during muscle differentiation and are deregulated in rhabdomyosarcoma.
    Fu W; Asp P; Canter B; Dynlacht BD
    Proc Natl Acad Sci U S A; 2014 Jun; 111(25):9151-6. PubMed ID: 24927541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.
    Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME
    Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel PAX3 rearrangement in embryonal rhabdomyosarcoma.
    Hosoi H; Kakazu N; Konishi E; Tsuchihashi Y; Hada S; Amaya E; Nakabayahi Y; Misawa-Furihata A; Tabata-Maruyama H; Iehara T; Sugimoto T; Yamane H; Yamasaki M; Shiwaku K; Yanagisawa A; Ono M; Tokiwa K; Iwai N; Hashiba M; Abe T; Sawada T
    Cancer Genet Cytogenet; 2009 Mar; 189(2):98-104. PubMed ID: 19215790
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DNA content and proliferative activity in pediatric genitourinary rhabdomyosarcoma.
    San Miguel-Fraile P; Carrillo-Gijón R; Rodríguez-Peralto JL; Ortiz-Rey JA; Alvarez-Alvarez C; de la Fuente-Buceta A
    Pediatr Pathol Mol Med; 2003; 22(2):143-52. PubMed ID: 12556294
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies.
    Chen Y; Takita J; Hiwatari M; Igarashi T; Hanada R; Kikuchi A; Hongo T; Taki T; Ogasawara M; Shimada A; Hayashi Y
    Genes Chromosomes Cancer; 2006 Jun; 45(6):583-91. PubMed ID: 16518851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.